Cholangiohepatitis in Dairy Cattle: 13 Cases

D.E. Gomez, E. Doré, D. Francoz, A. Desrochers, H. Pierre, and G. Fecteau

Background: The signalment, clinicopathologic, bacteriological, histopathological, ultrasonographic characteristics, and the treatment and outcomes of adult cattle with cholangiohepatitis are poorly defined.

Animals: Thirteen Holstein cows with cholangiohepatitis.

Methods: Retrospective study of medical records of cattle admitted to the CHUV and the AVC between 1992 and 2012 and 2000 and 2012, respectively, for cattle older than 3 months of age with a histopathological diagnosis of cholangiohepatitis. Cholangiohepatitis was defined as the presence of portal inflammation surrounding or infiltrating bile ducts, with or without epithelial damage, and extending into the adjacent lobules.

Results: At the time of diagnosis of cholangiohepatitis, cows had decreased appetite (n = 7) or were anorectic (n = 6), had fever (n = 5), and had tachycardia (n = 8). Icterus was detected in 5 cows. Yellow discoloration was identified on the skin of the udder (n = 3), conjunctiva (n = 2), and vulva (n = 1). There was leukocytosis (n = 6), neutrophilia (n = 9), and hyperfibrinogenemia (n = 8). Alteration in the serum biochemistry profile included hyperglobulinemia (n = 8), hypoalbuminemia (n = 10), increased activity of GGT (n = 12), AST (n = 8), and ALP (n = 10), and hyperbilirubinemia (n = 10). Histopathological diagnosis included mild, subacute, nonsuppurative cholangiohepatitis (n = 4), mild suppurative cholangiohepatitis (n = 4), mild mixed (neutrophilic and lymphocytic) cholangiohepatitis (n = 3), and moderate, chronic, nonsuppurative cholangiohepatitis (n = 1). Six cows were discharged from the hospital, and 7 were euthanized.

Conclusions and Clinical Importance: Cholangiohepatitis is a rare condition in adult cattle. Antemortem diagnosis can be challenging because clinical signs are unspecific.

Key words: Cholangitis; Cholestasis; Hepatic; Icterus.

Do diseases of the biliary tract such as cholecystitis, cholangitis, and cholangiohepatitis in cattle are rare and result from both intrahepatic and extrahepatic causes. By definition, cholecystitis describes the inflammation of the gallbladder and cholangitis describes the inflammation of the bile ducts. Almost inevitably, inflammation from the ducts spreads to the perportal hepatic parenchyma, creating lesions that can accurately be regarded as cholangiohepatitis. Anecdotal reports have associated cholangiohepatitis with abdominal fat necrosis, cholelithiasis, fascioliasis, foreign bodies, liver abscesses, neoplasia, and suppurative cholecystitis. Cattle grazing on turnips or other brassica forage crops occasionally develop cholangiohepatitis. Suppurative inflammation and ascending biliary tract infection by a wide variety of bacteria (both Gram-negative and Gram-positive enteric bacteria) have also been associated with cholangiohepatitis in cattle. However, there are a limited number of reports in the literature describing cholangiohepatitis in cattle. Therefore, the objective of this retrospective study was to describe the signalment, history, clinicopathologic, bacteriological, and postmortem findings as well as treatments and outcomes of adult cattle diagnosed with cholangiohepatitis at the Centre hospitalier universitaire vétérinaire (CHUV) de l’Université de Montréal and the Atlantic Veterinary College (AVC), University of Prince Edward Island, Canada.

Materials and Methods

We searched medical records of cattle admitted to the CHUV and the AVC between 1992 and 2012 and 2000 and 2012, respectively, for cattle older than 3 months of age with a histopathological diagnosis of cholangiohepatitis. Cholangiohepatitis was defined as the presence of portal inflammation surrounding or infiltrating bile ducts, with or without epithelial damage, and extending into the adjacent lobules. Records from cows with suspected cholangiohepatitis but missing liver biopsy or postmortem examination results were excluded.

We systematically reviewed medical records and extracted information about: age, sex, breed, month and year of hospitalization,
presenting complaint, clinical signs before hospital admittance, and lactation stage. Data from clinical signs, complete blood count (CBC), serum biochemistry profile (SBP), and ultrasonographic findings from the date immediately before liver biopsy were performed or when cholangiohepatitis was included as a differential diagnosis was recorded. Information on liver biopsy, bacteriological culture, treatments, duration of hospitalization, and outcome was collected. Postmortem findings were reviewed.

Results

Signalment and History

At CHUV, 12 of 5,519 cases met inclusion criteria, whereas at AVC, 1 of 245 patients was included. The diagnosis of cholangiohepatitis was confirmed ante-mortem from a liver biopsy in 12 cases and during post-mortem examination in 1 case. Cases included 12 Holstein cows and 1 Holstein heifer. The median age was 4 years (range: 0.4–7 years). Information regarding the lactation status was available for eleven of the twelve cows. Six cows were in the first 150 days of lactation, 1 cow was over 150 days of lactation, and 4 cows were dry. Reasons for veterinary consult included the following: fever (n = 5), decreased appetite (n = 4), colic (n = 2), stranguria (n = 1), sunburns (n = 1), right displacement of the abomasum (n = 1), and decreased milk and fecal output after omentopexy (n = 1).

Physical Examination

At the time of diagnosis of cholangiohepatitis, 6 cows were anorectic and 7 had decreased appetite. The median rectal temperature was 39°C (range: 37.7–40°C) and 5 cows were febrile (temperature >39.2°C). Median heart rate was 92 beats per minute (bpm) (range: 60–110 bpm), and 8 cows were tachycardic (HR >80 bpm). Icterus was detected in 5 cows. Yellow discoloration was identified on the skin of the udder (n = 1), strunguria (n = 1), sunburns (n = 1), right displacement of the abomasum (n = 1), and decreased milk and fecal output after omentopexy (n = 1).

Clinicopathological Findings

Hematologic findings included leucocytosis (>12 × 10⁹ cells/L) in 6 cases (median: 11 × 10⁹ cells/L, range: 6–26 × 10⁹ cells/L), neutrophilia (>4 × 10⁹ cells/L) in 9 cases (median: 8 × 10⁹ cells/L, range: 2.3–19 × 10⁹ cells/L), toxic changes identified in the neutrophil morphology in 4 cases, and hyperfibrinogenemia (>5 g/L) in 8 cases (median: 7 g/L, range: 3–11 g/L). Alteration in the SBP included hyperglobulinemia (>4.5 g/L) in 8 cases (median: 48 g/L, range: 20–65 g/L), hypoalbuminemia (<30 g/dL) in 10 cases (median: 28 g/L, range: 19–35 g/L), increased GGT activity (>39 IU/L) in twelve cases (median: 156 IU/L, range: 30–2,137 IU/L), AST (>127 IU/L) in 8 cases (median: 156 IU/L, range: 40–1,411 IU/L), and ALP (>100 IU/L) in 10 cases (median: 165 IU/L, range: 34–385 IU/L). SDH activity values were available for 7 cases with 5 cases having increased SDH activity (>12 IU/L, median: 24, range 4–2,309 IU/L). Hyperbilirubinemia (>14 µmol/L) was detected in 10 cases (median 53 µmol/L, range 7–188 µmol/L). In this study, 4 of 5 cases with icterus had a bilirubin concentration >77 µmol/L (range: 77–188 µmol/L), whereas 7 of 8 cases without icterus had a bilirubin concentration of 124 µmol/L, whereas 7 of 8 cases without icterus had a bilirubin concentration <56 µmol/L (range: 7–56 µmol/L). Icteric serum was noted in 5 cases. Serum bilirubin concentrations of all cases with icteric serum were >77 µmol/L (range: 77–188 µmol/L). Serum liver enzyme activity and bilirubin concentration from the time that cholangiohepatitis was suspected to the day of discharge or euthanasia were available in 6 cases (4 survivors and 2 nonsurvivors). Despite the clinical improvement of 6 surviving cases, a marked improvement in the serum activity of hepatobiliary enzymes or hyperbilirubinemia was not noted during hospitalization.

Ultrasonographic Findings

Transabdominal ultrasonographic examination results were available in 7 cases. Subjective abnormal findings included distension of the gallbladder (n = 4), increased thickness of the wall of the gallbladder (n = 3), presence of sediment in the gallbladder occupying two-thirds of the volume of the gallbladder (n = 2), and increased diameter of the bile duct (n = 3).

Liver Biopsy Findings

Liver biopsy and bacteriological culture were performed in twelve of thirteen cases. Final histopathological diagnosis, using the description suggested previously, included mild, subacute, nonsuppurative cholangiohepatitis (n = 2), mild, chronic, nonsuppurative cholangiohepatitis (n = 2), mild or severe, subacute, suppurative cholangiohepatitis (n = 4), mild mixed (neutrophilic and lymphocytic) cholangiohepatitis (n = 3), and moderate, chronic, suppurative cholangiohepatitis (n = 1).

Bacteriological Culture Findings

Bacteriological culture from liver biopsy tissue yielded growth in 3 of twelve cases in which it was performed. Bacterial isolation included Bacteroides spp. (n = 1), E. coli (n = 1), E. coli, and Trueperella pyogenes (n = 1). In 1 animal, culture of the liver tissue obtained on necropsy yielded growth of a multidrug resistant E. coli. In 2 animals in which bacteriological cultures from liver biopsy were negative, however, Salmonella spp. was cultured from a fecal sample submitted during their hospitalization. Antimicrobial therapy was administered before biopsy procedure in 8 of twelve cows.
Comorbidities

In addition to cholangiohepatitis, other diseases diagnosed included peritonitis (n = 3), photosensitization (n = 2), salmonellosis (n = 2), abomasal dilatation/dilataion (n = 2), glomerulonephritis (n = 1), pyelonephritis (n = 1), enteritis of unknown origin (n = 1), and bronchopneumonia (n = 1).

Treatment and Hospitalization Time

Treatment consisted of administration of broad-spectrum antibiotic treatment and supportive treatment with intravenous or oral fluids (12/13). Antimicrobial therapy included procaine benzyl penicillin (22,000 U/kg, IM q12h) (n = 10), trimethoprim-sulfadixine (TMS, 16 mg/kg IV q12h) (n = 4), oxytetracycline (11 mg/kg IV or IM q12h) (n = 3), ampicillin (10 mg/kg IV q8h) (n = 2), ceftiofur (1 mg/kg IM q24h) (n = 2), and lincomycin (dose was not recorded) (n = 1). The number of days (median) of treatment with antimicrobials was 10 (range: 1–35 days). For surviving cases, the number of days of antimicrobial therapy ranged from 4 to 35 days. Two cows underwent a laparotomy—1 was to correct a right abomasal displacement, and the second was an exploratory laparotomy. In the exploratory laparotomy, a large distended gallbladder was palpated and no other abnormal findings were detected. After surgery, the cow developed suppurative peritonitis and bilirubin and biliary acids were detected on abdominocentesis.

Outcome

Six cows were discharged from the hospital, whereas 7 were euthanized most likely due to poor prognosis or poor response to the instituted therapy. Three of 7 euthanized cows had chronic changes on the histopathological examination, and 1 had severe suppurative cholangiohepatitis. The median time of hospitalization for the surviving cows was 9.5 days (range: 8–12 days). The median time of hospitalization for non-surviving cows was 24 hours (range 1–10 days). Long-term follow-up was not studied for the surviving cattle.

Postmortem Examination Findings

Postmortem examination was performed for 7 cows. The most common macroscopic lesion was a mild-to-severe increase in thickness of the gallbladder wall (n = 6). The presence of blood clots in the gallbladder was observed in 3 cows. The mucosal surface of the gallbladder showed different grades of multifocal ulceration and coalesced areas of ulceration with or without hemorrhage. Fibrin plaques admixed with necrotic material were commonly identified in the gallbladder (n = 4). In 2 cases, peritonitis and adhesions from the duodenum to the liver leading to obstruction of the bile flow were confirmed. Adhesions producing obstruction of the bile flow after omentopexy was confirmed in 1 case. Peritonitis of unknown origin was identified in 2 cases, but in both cases, peritonitis was suspected to have occurred after bile flow obstruction. One cow was diagnosed with pyelonephritis, and 1 cow had glomerulonephritis.

Discussion

The proportion of cattle diagnosed with cholangiohepatitis in this study confirmed that the disease appears to be rare. It is possible that the low prevalence of cholangiohepatitis found in this retrospective study could have been biased by the chosen case definition. The diagnosis of cholangiohepatitis was established based on the histopathological findings on a liver biopsy or postmortem examination. Some cases of suspected cholangiohepatitis based on history, clinicopathologic examination, ancillary test, and ultrasonographic examination could have been treated symptomatically without a liver biopsy being performed, and therefore, some potential cases were likely missed. Also, postmortem examination archives at the teaching hospitals compile only the 2 or 3 most important diagnoses in each case. Those cases in which cholangiohepatitis was an incidental finding could also have been missed. Doing a search directly in the pathology records could have minimized this bias.

Cholangiohepatitis can be a primary or secondary disease. In healthy cattle, a relatively sterile biliary duct system is preserved by the continuous flow of bile from the gallbladder and biliary tree through the sphincter of Oddi into the duodenum. Primary cholangiohepatitis results from alteration of the normal bile flow, which leads to the ascending bacterial colonization of the biliary and hepatic tissue and results in cholangitis and cholangiohepatitis. Secondary cholangiohepatitis results from obstruction of normal bile flow due to external mechanical pressure exerted on the common bile duct by liver abscesses, by extensive adhesions in the area of the cystic and common bile ducts, or by severe inflammatory lesions of the common duct near the hilus or the duodenal papilla.

Due to the retrospective nature of this study, it was not possible to accurately determine in which cases primary or secondary cholangiohepatitis occurred. However, primary cholangiohepatitis was suspected in 4 cows in which comorbidities were not identified on physical or postmortem examination. Two of those cows had photosensitization as the principal complaint and was considered to be secondary to cholangiohepatitis and liver insult. The other 2 cows had acute septic peritonitis as the principal diagnosis, suspected to have resulted from a primary biliary obstruction. Secondary cholangiohepatitis was suspected in 9 cases where comorbidities were identified on physical examination, postmortem examination, or both. Comorbidities that could have resulted in secondary cholangiohepatitis included enteritis, adhesions of the small intestine blocking the biliary duct, renal infections, and abomasal displacement.

The clinical signs of the cows with cholangiohepatitis reported in this study included anorexia, obtundation, fever, and colic. Although these signs are nonspecific,
they are observed consistently with cholangiohepatitis in different species.9–11 Icterus is also commonly reported in cases of cholangiohepatitis.9,10 It has been suggested that clinical icterus in cattle develops when serum bilirubin is greater than 51 μmol/L.8 In this study, icterus was present in 5 of 13 cows and serum bilirubin concentrations were greater than 77 μmol/L in 4 of these 5 cows. Further, icteric serum was identified in 5 cows in which serum bilirubin was >77 μmol/L. These results support the current understanding that a marked increase in serum bilirubin occurs before jaundice becomes easily recognized.8

In this study, the majority of cows had increased activity of at least 5 variables (bilirubin, GGT, AST, ALP, and SDH). GGT, ALP, and bilirubin were consistently increased, demonstrating insult of the biliary tree. Neutrophilia, hyperbilirinogenemia, and hyperglobuline mia were also common findings consistent with an active inflammatory process. These findings were expected as it was likely that those changes prompted the clinicians to proceed with a liver biopsy to confirm the presence of cholangiohepatitis. Increased activity of hepatobiliary enzymes or hyperbilirubinemia or both conditions are commonly reported in cases of cholangiohepatitis. Similar results have been reported in both horses and cattle with cholangiohepatitis.3,11–13 It is possible that co morbidity such as peritonitis, pyelonephritis, or glomerulonephritis can also contribute to increases in inflammatory markers. Importantly, cows suffering with hepatic lipidosis in combination with an inflammatory process (e.g., acute metritis or mastitis) can have similar laboratory results to the cattle with cholangiohepatitis found in this study. Therefore, the changes in CBC and SBP are not specific to cholangiohepatitis.

During ultrasonographic examination, distension of the gallbladder alone is not an indication of cholestasis as the volume of the gallbladder increases without any impairment of bile flow in anorexic cattle.14 Abnormal gallbladder content, such as sediment or concretion, without thickening of the wall of the gallbladder can also be observed in anorexic cows with various diseases not specific to the liver.15 However, distension of the gall bladder in combination with thickening of the wall and sediment due to inflammation suggests disease such as cholangiohepatitis.14,16,17 Ultrasonographic findings compatible with cholangiohepatitis in cattle included distension and increased thickness of the wall of the gallbladder with the presence of sediment and increased diameter of the bile canaliculi.

In cattle with suspected cholestasis, the diagnostic approach should also include the histologic and bacteriological examination of a liver biopsy specimen. All the liver biopsy samples in this study, in contrast to aerobic and anaerobic culture, but only 3 samples yielded a positive result. These results are similar to those reported in horses. For instance, a previous study in horses with cholangiohepatitis revealed that only 2 of 9 liver biopsy samples submitted for both aerobic and anaerobic culture yielded a positive result. Negative bacteriological cultures were obtained in horses with or without receiving prebiopsy antimicrobials.13 It is possible that antimicrobial therapy administered before the biopsy procedure prevents positive results. However, culture can be negative in horses with cholangiohepatitis even in the absence of prior antimicrobial therapy.

In the present study, liver samples and gallbladder content yielded growth of E. coli, Trueperella pyogenes and Bacteroides spp. These findings were not unexpected. Several studies in humans, horses, dogs, and cattle have reported that Gram-negative bacilli are frequently encountered in patients with cholangiohepatitis, cholelithiasis or both. Bile cultures are positive in 80–100% of humans who have cholangiohepatitis.18 Enteric Gram-negative organisms including E. coli, Klebsiella spp., and Enterococcus spp. are commonly isolated from bile, and anaerobic bacteria such as Clostridium spp. and Bacteroides spp. are isolated more commonly in polymicrobial infections in humans who have severe disease.13,19–21 Gram-negative enteric bacteria, such as E. coli, Salmonella spp., Aeromonas spp., Bacteroides spp., and Citrobacter spp., are associated with cases of cholangiohepatitis. Increased activity of at least 5 variables (bilirubin, GGT, AST, ALP, and SDH) is expected as it was likely that those changes prompted the clinicians to proceed with a liver biopsy to confirm the presence of cholangiohepatitis. Additionally, reported in previous reports of cholangiohepatitis in dogs were E. coli, Klebsiella spp., and Clostridium spp., which are all normal constituents of the intestinal flora.22 In this study, Salmonella spp. was isolated from the feces, but not from liver tissue, of 2 cows suffering from enteritis, however, whether salmonella was the cause of cholangiohepatitis remains unclear.

Treatment in all cases was similar and consisted of antimicrobial therapy and supportive medical care. All 6 surviving cases were treated medically. In human medicine, medical treatment without surgery is effective in approximately 80% of patients.23,24 Therapy of 6 days is not in the literature regarding cholangitis and cholangiohepatitis in dogs in which 4 of 6 responded to medical treatment alone.9,22,23 In human medicine, antibiotics are given early when acute cholangitis is suspected. In this study, in surviving cases, the number of days on antimicrobial therapy ranged from 4 to 35 days. In human medicine, broad-spectrum antibiotics with adequate biliary excretion such as ampicillin, potentiated sulphas, and third- or fourth-generation cephalosporins and quinolones are widely used in empirical antimicrobial therapy of biliary tract infection.24–26 Antimicrobial therapy for cattle suffering from cholangiohepatitis should be started based on culture and sensitivity results from liver biopsy. However, in clinical practice, empirical antimicrobial therapy often needs to be instituted before culture results are available and must respect the judicious use of antibiotics. Initial treatment options for cattle with cholangiohepatitis include aminopenicillins (amoxicillin), potentiated sulphas (trimethoprim-sulphadiazine, where allowed), third-generation cephalosporins (ceftiofur) as biliary excretion is one of the major routes of elimination for these antimicrobials.27 Tetracycline can also be used for treatment of cholangiohepatitis. Tetracyclines are excreted in bile, they are reabsorbed from the intestine and returned to the liver (enterohepatic cycle) for reentry into systemic circulation.28 Once
the microorganisms have been identified and their susceptibility has been determined, the antimicrobials should be adjusted to cover the identified microorganism. The duration of antimicrobial therapy for surviving cows ranged from 4 to 35 days. In humans, the duration of antimicrobial therapy is based on the clinical response and the presence of bacteremia. For mild disease, antibiotics are generally continued for 5–7 days and for patients who have a positive blood culture, a 10–14 day course of antibiotics is recommended. Long-term parenteral antimicrobials were associated with survival in horses and dogs. In this study, clinical improvement in surviving cattle during hospitalization was noted despite of a persistent increased in hepatobiliary enzyme activity and hyperbilirubinemia. Therefore, extended antimicrobial could be beneficial for cattle with cholangiohepatitis; however, the optimal duration of antimicrobial therapy in cattle cannot be withdrawn from the present study and remains to be established.

The pathological grading system failed to demonstrate any association between the severity and chronicity of the lesion and prognosis. Similar observations have been reported in horses. It appeared that the diagnosis of cholangiohepatitis carried a guarded prognosis, at least in the small group of hospitalized cattle included in this study. It is possible that this study had a bias toward sicker patients, but such cattle seem to be representative of the population presented to referral teaching hospitals. The prognosis for cholangiohepatitis in dogs and horses appeared to be good, with most of the cases making a full recovery. Based on the information registered in the medical records used in this study, it was not possible to determine whether the reason for euthanasia was primarily cholangiohepatitis or comorbidities or both, and further deductions could not be drawn.

In conclusion, the results of this study revealed that cholangiohepatitis is a rare condition in adult cattle. Antemortem diagnosis may be challenging because clinical signs and laboratory results are unspecific. Diagnostic processes should include clinical history collection, physical examination, hematologic and serum biochemistry profile, ultrasonography imaging, and liver biopsy with bacteriological culture and histopathology examination. Initial treatment should include antimicrobials and supportive intravenous fluid therapy.

Acknowledgments

Conflict of Interest Declaration. Authors declare no conflict of interest.

Off-label Antimicrobial Declaration. Authors declare no off-label use of antimicrobials.

References

1. Van Metre DC, Tennant BC, Whitlock RH. Infectious Diseases of the Gastrointestinal Tract. In: Divers T, Peek S, eds. Rehun’s Diseases of Dairy Cattle, 2nd ed. St. Louis: Saunders Elsevier; 2008:200–294.

2. Maxi MG. Inflammatory diseases of the liver and biliary tract. In: Maxi MG, ed. Jubb, Kennedy & Palmer’s Pathology of Domestic Animals, 6th ed. Elsevier: St Louis, Missouri: 2007:337–348.

3. Davis JL. Gallbladder and biliary tract diseases. In: Smith B, ed. Large Animal Internal Medicine, 5th ed. Mosby Elsevier: St. Louis Missouri: 2015:869–870.

4. Collett MG. Bile duct lesions associated with turnip (Brassica rapa) photosensitization compared with those due to sporidesmin toxicity in dairy cows. Vet Pathol 2014;51:986–991.

5. Whitlock RH, Brown WR. Chronic cholangiohepatitis in a dairy cow. A case report. Cornell Vet 1969;59:515–524.

6. Coombs DK, MacWilliams PS, Phillips LA, et al. Cholangiohepatitis in a calf. Vet Rec 2002;150:551–552.

7. Dohoo I, Martin S, Stryhn H. Veterinary Epidemiologic Research, 2nd ed. Charlottetown, CA: AVC Inc.; 2003.

8. Tennant BC, Center SA. Hepatic function. In: Kaneko JJ, Harvey JW, Bruss ML, eds. Clinical Biochemistry of Domestic Animals, 6th ed. Burlington: Academic Press Elsevier; 2008:379–412.

9. O’Neill EJ, Day MJ, Hall EJ, et al. Bacterial cholangitis/cholelithiasis in horses with or without concurrent cholecystitis in four dogs. J Small Anim Pract 2006;47:325–335.

10. Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:52–58.

11. Davis JL, Jones SL. Suppurative cholangiohepatitis and enteritis in adult horses. J Vet Intern Med 2003;17:583–587.

12. Dore E, Fectueu G, Hele P, Francoz D. Liver abscesses in Holstein dairy cattle: 18 cases (1992–2003). J Vet Intern Med 2007;21:853–856.

13. Peek SF, Divers TJ. Medical treatment of cholangiohepatitis and cholelithiasis in mature horses: 9 cases (1991–1998). Equine Vet J 2000;32:301–306.

14. Braun U. Ultrasonography of the liver in cattle. Vet Clin North Am Food Anim Pract 2009;25:591–609.

15. Braun U, Pospischil A, Pusterla N, Winder C. Ultrasonographic findings in cows with cholelithiasis. Vet Rec 1995;137:537–543.

16. Spaulding KA. Gall bladder wall thickness. Vet Radiol Ultrasound 1993;34:270–272.

17. Center SA. Diseases of the gallbladder and biliary tree. Vet Clin North Am Small Anim Pract 2009;39:543–598.

18. van Erpecum KJ. Complications of bile-duct stones: Acute cholangitis and pancreatitis. Best Pract Res Clin Gastroenterol 2006;20:1139–1152.

19. Karvellas CJ, Abraldes JG, Zepeda-Gomez S, et al. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock. Aliment Pharmacol Ther 2016;44:755–766.

20. Zimmer V, Lammert F. Acute bacterial cholangitis. Viszeralmedizin 2015;31:166–172.

21. Attasaranya S, Fogel EL, Lehman GA. Choledocholithiasis, ascending cholangitis, and gallstone pancreatitis. Med Clin North Am 2008;92:925–960.

22. Ramery E, Papakonstantinou S, Pinilla M, et al. Bacterial cholangiohepatitis in a dog. Can Vet J 2012;53:423–425.

23. Forrester SD, Rogers KS, Relford RL. Cholangiohepatitis in a dog. J Am Vet Med Assoc 1992;200:1704–1706.

24. Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo guidelines. J Hepatobiliary Pancreat Surg 2007;14:59–67.

25. Tazuma S, Igarashi Y, Inui K, et al. BTI Therapy Research Group. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: A multicenter, randomized, controlled
trial with imipenem/cilastatin as comparator. J Gastroenterol 2015;50:221–229.

26. Nishino T, Hamano T, Mitsunaga Y, et al. Clinical evaluation of the Tokyo Guidelines 2013 for severity assessment of acute cholangitis. J Hepatobiliary Pancreat Sci 2014;21:841–849.

27. Baggot JD, Giguere S. Principles of antimicrobial drug bioavailability and disposition. In: Giguere S, Prescott JF, Dowling PM, eds. Antimicrobial Therapy in Veterinary Medicine, 5th ed. Ames: Wyley Blackwell; 2013:41–77.

28. Weese JS, Giguère S, Guardabassi L, et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet Intern Med 2015;29:487–498.